Brokerage firm Feltl & Co. Upgrades its rating on Novadaq Technologies(NASDAQ:NVDQ). The shares have been rated Strong Buy. Previously, the analysts had a Buy rating on the shares. The rating by Feltl & Co. was issued on Jul 28, 2016.
Novadaq Technologies (NVDQ) made into the market gainers list on Thursdays trading session with the shares advancing 1.81% or 0.19 points. Due to strong positive momentum, the stock ended at $10.71, which is also near the day’s high of $10.73. The stock began the session at $10.48 and the volume stood at 1,23,511 shares. The 52-week high of the shares is $14.36 and the 52 week low is $8.26. The company has a current market capitalization of $615 M and it has 5,74,35,445 shares in outstanding.
Novadaq Technologies(NVDQ) last announced its earnings results on Jul 27, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $20.12M. Analysts had an estimated revenue of $19.93M. Earnings per share were $-0.29. Analysts had estimated an EPS of $-0.14.
Novadaq Technologies Inc. develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company’s imaging platform can be used to visualize blood vessels nerves and the lymphatic system during surgical procedures. The Company generates revenues from the sale of medical devices and consumables capital devices or consumable products the rental of capital devices royalties upfront payments received from partners for exclusive sales and marketing rights and extended warranty services agreements in connection with capital sales. The Companys SPY imaging products are SPY Elite FIREFLY LUNA PINPOINT CO2 HEART LASER systems and DermACELL Advanced Decellularized Dermis. The SPY Imaging System is United States Food and Drug Administration (FDA) cleared for use in seven surgical specialties including coronary artery bypass cardiovascular plastic reconstructive micro organ transplant and gastrointestinal surgery.